TcrossGlobal

Impella Versus Non-Impella for Nonemergent High-Risk Percutaneous Coronary Intervention

Compared with patients enrolled in the PROTECT III trial, which evaluated the use of Impella in high-risk PCI (HR-PCI), patients treated without Impella who met the criteria had no difference in in-hospital MACE rates but showed a lower rate of MACE at 90 days, Dr. Pavan Reddy and colleagues, MedStar Washington Hospital Center, USA, reported in the August 15 issue of the American Journal of Cardiology.

High-risk PCI patients who met the inclusion criteria for the PROTECT III trial were retrospectively...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.